Dorottya Ádám

Ms. Dorottya Ádám

University of Debrecen, Debrecen, Hajdú-Bihar, Hungary
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2019 in Molecules
Verified
Journal Article
Open access
PDF file
TFTóth Kinga Fanni
Tóth Kinga Fanni
Dorottya ÁdámDorottya Ádám
Dorottya Ádám
TBTamás Bíró
Tamás Bíró
Attila OláhAttila Oláh
Attila Oláh
The endocannabinoid system (ECS) has lately been proven to be an important, multifaceted homeostatic regulator, which influences a wide-variety of physiological processes all over the body. Its members, the endocannabinoids (eCBs; e.g., anandamide), the eCB-responsive receptors (e.g., CB1, CB2), as well as the complex enzyme and transporter apparatus involved in the metabolism of the ligands were shown to be expressed in several tissues, including the skin. Although the best studied functions over the ECS are related to the central nervous system and to immune processes, experimental efforts over the last two decades have unambiguously confirmed that cutaneous cannabinoid (“c[ut]annabinoid”) signaling is deeply involved in the maintenance of skin homeostasis, barrier formation and regeneration, and its dysregulation was implicated to contribute to several highly prevalent diseases and disorders, e.g., atopic dermatitis, psoriasis, scleroderma, acne, hair growth and pigmentation disorders, keratin diseases, various tumors, and itch. The current review aims to give an overview of the available skin-relevant endo- and phytocannabinoid literature with a special emphasis on the putative translational potential, and to highlight promising future research directions as well as existing challenges.

1 October 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
AMArnold Markovics
Arnold Markovics
ÁAÁgnes Angyal
Ágnes Angyal
TFTóth Kinga Fanni
Tóth Kinga Fanni
Dorottya ÁdámDorottya Ádám
Dorottya Ádám
ZPZsófia Pénzes
Zsófia Pénzes
Attila OláhAttila Oláh
Attila Oláh

Verified
Journal Article
Open access
PDF file
Dorottya ÁdámDorottya Ádám
Dorottya Ádám
JAJózsef Arany
József Arany
TFTóth Kinga Fanni
Tóth Kinga Fanni
BTBalazs Istvan Toth
Balazs Istvan Toth
Attila Gábor SzöllősiAttila Gábor Szöllősi
Attila Gábor Szöllősi
Attila OláhAttila Oláh
Attila Oláh
Atopic dermatitis (AD) is one of the most common skin diseases, the prevalence of which is especially high among children. Although our understanding about its pathogenesis has substantially grown in recent years, and hence, several novel therapeutic targets have been successfully exploited in the management of the disease, we still lack curative treatments for it. Thus, there is an unmet societal demand to identify further details of its pathogenesis to thereby pave the way for novel therapeutic approaches with favorable side effect profiles. It is commonly accepted that dysfunction of the complex cutaneous barrier plays a central role in the development of AD; therefore, the signaling pathways involved in the regulation of this quite complex process are likely to be involved in the pathogenesis of the disease and can provide novel, promising, yet unexplored therapeutic targets. Thus, in the current review, we aim to summarize the available potentially AD-relevant data regarding one such signaling pathway, namely cutaneous opioidergic signaling.

5 February 2026 in Journal of Cannabis Research
Verified
Journal Article
Open access
PDF file
FPFerenc Dániel Petróczi
Ferenc Dániel Petróczi
ATAngéla Tótik
Angéla Tótik
MBMiklós Bege
Miklós Bege
JKJózsef Király
József Király
SESzabó Erzsébet
Szabó Erzsébet
IBIlona Bereczki
Ilona Bereczki
Background: Cannabidiol (CBD) and cannabigerol (CBG) are non-psychotropic phytocannabinoids that have significant, broad-spectrum therapeutic potential in a variety of pharmacological areas, but their unfavorable pharmacokinetics, such as extensive first-pass metabolism and low bioavailability, hinder their effective medical applications. Therefore, there is a great need for appropriate chemical modifications to improve their physicochemical properties. Incorporation of fluorine atom(s) at appropriate positions often improves the metabolic stability of the parent compound, increasing its bioavailability, and enhances its binding affinity to therapeutic targets, making fluorine a highly valuable element in modern drug development. Furthermore, amino functional groups may improve the water solubility and bioavailability of the compounds. Building on these principles, our strategy focused on introducing groups containing mono-, di-, and trifluoroethylamine or fluorinated aniline moieties into cannabinoids to improve their pharmacokinetic and pharmacological profiles. Methods: Mannich-type reaction was applied, using commercially available 2-fluoroethylamine, 2,2-difluoroethylamine, 2,2,2-trifluoroethylamine, 3-fluoroaniline and 4-fluoroaniline as reagents. One or two oxazine rings with fluorine-containing side chains were condensed to the aromatic core of the cannabinoids, and the formation of mono- or disubstituted derivatives was controlled by the appropriate choice of reaction conditions. The biological activity of the derivatives was investigated in various relevant fields. Results and conclusion: Our findings indicate that aliphatic modifications positively influence pharmacokinetic parameters, including absorption, in contrast to aromatic groups, which increase lipophilicity and lead to decreased bioavailability. Among the modifications, the monosubstituted derivatives containing a single oxazine ring with an aliphatic fluorine-containing side chain, especially the mono- and trifluoroethyl moieties, proved to be the most promising. These modifications appeared particularly advantageous in the CBG series compared to the properties of the CBG parent compound. This may suggest that the presence of a phenolic OH group is beneficial for biological activity. Some of the derivatives showed anticancer potential against various tumor cell lines, while others modulated sebaceous lipogenesis, and certain compounds exhibited a notable antimalarial effect.

21 December 2023 in Experimental Dermatology
Verified
Journal Article
Open access
TFTóth Kinga Fanni
Tóth Kinga Fanni
Dorottya ÁdámDorottya Ádám
Dorottya Ádám
JAJózsef Arany
József Arany
YRYesid A. Ramirez
Yesid A. Ramirez
TBTamás Bíró
Tamás Bíró
Attila OláhAttila Oláh
Attila Oláh
Fluoxetine is a safe antidepressant with remarkable anti‐inflammatory actions; therefore, we aimed to investigate its effects on immortalized (HaCaT) as well as primary human epidermal keratinocytes in a polyinosinic‐polycytidylic acid (p(I:C))‐induced inflammatory model. We found that a non‐cytotoxic concentration (MTT‐assay, CyQUANT‐assay) of fluoxetine significantly suppressed p(I:C)‐induced expression and release of several pro‐inflammatory cytokines (Q‐PCR, cytokine array, ELISA), and it decreased the release of the itch mediator endothelins (ELISA). These effects were not mediated by the inhibition of the NF‐κB or p38 MAPK pathways (western blot), or by the suppression of the p(I:C)‐induced elevation of mitochondrial ROS production (MitoSOX Red labeling). Instead, unbiased activity profiling revealed that they were most likely mediated via the inhibition of the phosphoinositide 3‐kinase (PI3K) pathway. Importantly, the PI3K‐inhibitor GDC0941 fully mimicked the effects of fluoxetine (Q‐PCR, ELISA). Although fluoxetine was able to occupy the binding site of GDC0941 (in silico molecular docking), and exerted direct inhibitory effect on PI3K (cell‐free PI3K activity assay), it exhibited much lower potency and efficacy as compared to GDC0941. Finally, RNA‐Seq analysis revealed that fluoxetine deeply influenced the transcriptional alterations induced by p(I:C)‐treatment, and exerted an overall anti‐inflammatory activity. Collectively, our findings demonstrate that fluoxetine exerts potent anti‐inflammatory effects, and suppresses the release of the endogenous itch mediator endothelins in human keratinocytes, most likely via interfering with the PI3K pathway. Thus, clinical studies are encouraged to explore whether the currently reported beneficial effects translate in vivo following its topical administration in inflammatory and pruritic dermatoses.

7 May 2025 in Experimental Dermatology
Verified
Journal Article
Open access
Dorottya ÁdámDorottya Ádám
Dorottya Ádám
JAJózsef Arany
József Arany
TFTóth Kinga Fanni
Tóth Kinga Fanni
OPOrsolya Pető
Orsolya Pető
TNTamara Nyitrai
Tamara Nyitrai
Attila OláhAttila Oláh
Attila Oláh
Transient receptor potential melastatin 5 (TRPM5) ion channel is expressed in human hair follicles, where its spontaneous activity contributes to the maintenance of the growing, anagen phase of the hair cycle. Because adjacent sebaceous glands also exhibited TRPM5 immunopositivity, topically applied TRPM5 modulators administered to influence hair growth may also affect sebaceous glands. Hence, we aimed to assess expression of TRPM5 as well as effects of TRPM5 modulators [activators: 2,5‐dimethylpyrazine, 2‐heptanone; antagonist: triphenylphosphine oxide (TPPO)] on human SZ95 sebocytes, i.e., on the best available in vitro model to study human sebaceous glands. First, using complementary methods [RNA‐Seq, RT‐qPCR, western blot, siRNA‐mediated gene silencing and fluorescent Na+‐ (SBFI AM) and Ca2+‐measurements (Fura‐2 AM)], we found that TRPM5 is not expressed in human sebocytes in a functionally active form. Importantly, while non‐cytotoxic (MTT‐assay) concentrations of the activators were ineffective, TPPO promoted sebaceous lipogenesis (Nile Red labelling). This effect was TRPM5‐independent and was found to be mediated in an Akt‐ and epidermal growth factor receptor (EGFR)‐dependent manner, most likely via the Akt‐induced up‐regulation of diacylglycerol O‐acyltransferase (DGAT)‐2. Moreover, TPPO up‐regulated interleukin (IL)‐6 in an EGFR‐ and p38α MAPK‐dependent manner (RT‐qPCR), whereas it decreased the release of IL‐8 (ELISA), and down‐regulated additional pro‐inflammatory cytokines [chemokine (C‐X‐C motif) ligand [CXCL]‐1, CXCL2, CXCL6, colony‐stimulating factor 2, IL‐32; RNA‐Seq]. Collectively, specific TRPM5 modulators are unlikely to exert direct sebaceous gland‐related side effects, while safe TPPO analogues may induce beneficial moderate lipogenic and anti‐inflammatory effects in dry skin dermatoses.